Molecule to Market, Driving AI Transformation

In this insightful session, Bruno Gagliardo, Senior Executive at Sanofi, unveils how AI-driven transformation is reshaping the pharmaceutical industry's traditional pathways from molecule discovery to market introduction. By embedding data and artificial intelligence throughout the drug development lifecycle, organizations can significantly accelerate innovation, reduce costs, and improve precision in clinical outcomes. The approach highlights the critical integration of cross-functional teams leveraging advanced analytics and machine learning to streamline decision-making processes and enhance research productivity.

Key leadership imperatives emerge around fostering a data-centric culture, investing in scalable AI infrastructure, and navigating regulatory complexities inherent in healthcare innovation. The session underscores the importance of ethical AI application and patient-centric design as foundational pillars. Leaders and policymakers alike should consider these frameworks to cultivate environments where innovation aligns with patient safety, compliance, and measurable business impact.

• Accelerating drug discovery through AI-enabled data integration
• Balancing innovation with regulatory and ethical requirements
• Building cross-disciplinary teams capable of driving AI transformation
• Strategic investments in scalable AI and data platforms for sustained competitive advantage